Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 ...

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008. “We have examined our sales organization in depth,” Adrian ...

Marlborough-based Sepracor Inc. has agreed to be acquired by Japanese drug firm Dainippon Sumitomo Pharma Co. for about $2.6 billion. Dainippon will purchase Sepracor in a cash tender offer of $23 per ...

Sepracor will launch a $60 million dollar marketing and advertising campaign for its new sleeping pill Lunesta in the coming week. Ads for the drug will tout Lunesta’s advantages, Sepracor chief ...

Mark Iwicki, the new president and COO at Sepracor, says the company, under new Japanese ownership, will focus on niche market drugs. PHOTO/COURTESY The $2.6 billion move for Dainippon Sumitomo Pharma ...

During the last year, Sepracor (SEPR) has had a substantial correction in price, dropping over fifty percent. This significant decline has taken the market cap of the company to only $3.11B. Even with ...

Two separate moves, by Sanofi-Aventis and Sepracor, illustrate the power that drug companies can have over the taxes of towns they base their headquarters in. Sanofi backed out of a deal in ...

Agreement provides Sepracor with a global license covering development of stable suspension formulations and nebule technology in ciclesonide inhalation solution for asthma and chronic obstructive ...

Spotted a moth lately? Fewer and fewer people have, and for good reason. Sepracor has started to cut back its consumer ads, making that familiar Lunesta moth something of an endangered critter. At ...

MARLBOROUGH, Mass. (CBS.MW) - Sepracor Inc. rose from obscurity to become a Wall Street darling in the late '90s as investors bet that the company could capture a big piece of the lucrative market for ...

Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of Sepracor and as Executive Officer of ...